From the Food and Drug Administration.
Nightingale
S L
SL
D017277:Drug Approval; D004893:Erythema Nodosum / Q000188:drug therapy*; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use*; D015440:Leprosy, Lepromatous / Q000188:drug therapy*; D011050:Policy Making; D013792:Thalidomide / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration / Q000458:organization & administration*
D007917:Leprostatic Agents; D013792:Thalidomide